Bayer plans 3 new drugs, banks on gene and cell therapy allogeneic cancer medicines

German pharma giant Bayer has plans to introduce three news drugs with annual sales potential of $1.22 billion (€1 billion) but these will not offset the fall in revenue the company anticipates from the loss of patents over its two best-sellers.

Stefan Oelrich, the company head, who joined in 2018 from rival Sanofi, acknowledged that the new drugs would not compensate for the effects of the forthcoming patent expiry on both its blood thinner Xarelto and eye medicine Eylea, which will start this year in stages globally. The two drugs generate more than €6bn ($6.2 billion) in annual sales, over a third of Bayer’s pharma revenue. “No company in the world . . . would be able to fill such a gap just at once,” said Oelrich at a media meet on Wednesday.

Bayer Pharma Giant

(Photo: Bayer AG)

Bayer recently announced a partnership with German vaccine maker CureVac to accelerate the development of a Covid-19 vaccine.

Bayer is still struggling from its ill-fated acquisition of Monsanto in 2016 and the slew of lawsuits it inherited for Monsanto’s weed killer Roundup’s carcinogenic effects.

Its share price has dropped by over 50 percent in the last five years. After agrichemicals business pharma is its second-largest revenue puller with annual sales of over €18 billion. “The pipeline is light, especially in oncology, but has some more promising products,” said Sebastian Bray, an analyst at Berenberg.

Bayer has turned its focus to cell and gene therapy in the last two years and spent over €5 billion in acquiring companies specializing in the research and development of these sciences.

“We are aiming to launch at least three new clinical substances per year,” Oelrich revealed. The approval processes in these spaces are less tedious and time-consuming and even the R&D cycles are shorter.

But for these investments to pay-off, it will take at least another four to five years. He said the medium-term impact could be larger, with Bayer working on seven promising cell and gene therapy products in clinical development. Bray said Bayer’s move into this new field was right: “Cell and gene therapy are the higher growth markets in pharma,” he said.

Bayer recently invested $105 million in a funding round in closely held Senti Biosciences, a California-based company using synthetic biology to develop off-the-shelf cell therapies for cancer. It is the third cell therapy company to receive investment from Bayer.

“We believe that synthetic biology will become an important pillar in next-generation cell and gene therapy, and that Senti Bio’s leadership in designing and optimizing biological circuits fits precisely with our ambition to prevent and cure cancer and to regenerate lost tissue function,” Juergen Eckhardt, head of Bayer’s venture arm, called Leaps by Bayer, said in a statement.

Bayer also initially took a minority stake in BlueRock Therapeutics before buying out the company in a $1 billion transaction. Leaps by Bayer also took part in a$215 funding round for Century Therapeutics.

The company is also banking on three new drugs with an annual sales potential of over €1bn. The drugs are—a cancer medicine named Nubeqa; a drug called Finerenone to treat diabetic kidney disease; and a drug to treat menopausal symptoms. The cancer drug has already been launched successfully, the kidney disease drug will be launched this year, and the third medicine is in the last stage of clinical trials and will be released in 2024, most likely.

Subscribe to the nation’s fastest-growing business magazine to get the latest business news delivered to your inbox. 

Anna Domanska
Anna Domanska is an Industry Leaders Magazine author possessing wide-range of knowledge for Business News. She is an avid reader and writer of Business and CEO Magazines and a rigorous follower of Business Leaders.

Recent Posts

Global Financial Markets hit by fears of US interest rate rise

Global Financial Markets hit by fears of US interest rate rise

US Federal Reserve is charging investors with inflationary pressures by putting up interest rates to create a response to the surging inflation.
11 hours ago
A Cryptocurrency CEO Has Become one of the World’s Wealthiest Billionaires

A Cryptocurrency CEO Has Become one of the World’s Wealthiest Billionaires

Changpeng Zhao, also known as CZ, is now the 11th richest person in the world with an estimated net worth of $96 billion.
12 hours ago
Rivian IPO: The Withdrawal After the Euphoria

Rivian IPO: The Withdrawal After the Euphoria

The stock was listed at $78 per share and later rose to $172.01 within five days. The Rivian IPO buoyed investor spirits and was the largest IPO in the US after 2014.
15 hours ago
The Facebook and Google Deal: The Blueprint of an Antitrust Investigation

The Facebook and Google Deal: The Blueprint of an Antitrust Investigation

Across Asia, Europe and the US, governments are reviewing laws to regulate how big tech companies operate. They are also filing and considering a number of antitrust investigations
1 day ago
5 New Year’s Resolutions for Entrepreneurs

5 New Year’s Resolutions for Entrepreneurs

Here are a few new year’s resolutions for entrepreneurs who wish to accomplish their goals for the better.
1 day ago
4 Important Leadership Skills for Workplace Success

4 Important Leadership Skills for Workplace Success

You can begin building your success by building these leadership skills and rally employees to work towards the company goals.
2 days ago